Table 1 Comparing the serum antibody levels against AP3D1 between healthy donors (HDs) and patients with AIS and TIA.

From: Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis

Subject information on HDs and patients with AIS and TIA

Sample information

HD

AIS

TIA

Total number

123

158

77

Male/Female

85/38

119/39

49/28

Age, years (average ± SD)

51.85 ± 8.74

57.99 ± 7.97

69.45 ± 11.64

Summary of serum AP3D1 antibody (s-AP3D1-Ab) levels examined by AlphaLISA in HDs and patients with AIS and TIA

Patient group

Type of value

s-AP3D1-Ab

HD

Average

13,471

SD

10,800

Cutoff values

35,072

Positive No

3

Positive (%)

2.40%

AIS

Average

18,810

SD

11,712

Positive No

16

Positive (%)

10.10%

P value (vs. HD)

 < 0.001

TIA

Average

20,506

SD

11,786

Positive No

8

Positive (%)

10.40%

P value (vs. HD)

 < 0.001

  1. The upper panel indicates the number of total samples, samples from male and female participants, and ages [average ± standard deviation (SD)]. The lower panel summarizes the serum AP3D1 antibodies (s-AP3D1-Abs) examined using amplified luminescence proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) using purified AP3D1 protein as an antigen. Cutoff values were determined as the average HDs values plus two SDs, and positive samples for which the antibody levels exceeded the cutoff value were scored. P-values were calculated using the Kruskal–Wallis test (Mann–Whitney U test with Bonferroni's correction applied). P-values of < 0.05 and positive rates of > 10% are marked in bold font. These data are plotted and shown in Fig. 1a,b.
  2. AP3D1 adaptor-related protein complex 3 subunit delta 1, s-AP3D1-Abs the serum anti-AP3D1 antibodies, AIS acute ischemic stroke, TIA transient ischemic attack.
Back to article page